李浩

德泰迈医药科技有限公司创始人和董事长

李浩, 医学博士，德泰迈创始人和董事长，泰格益坦创始人，曾任泰格医药首席医学官，清华大学医学院行业授课教师和硕导, 交大医学院客座教授和临床研究中心顾问，亦弘商学院客座教授，中国区ICH工作组专家。参与国家药物审评中心的培训和多项技术指南和管理办法的制定。曾担任昆泰，雅培制药，赛诺菲巴斯德，施贵宝，和Amylin等公司总部的经理到资深医学总监。具有20年临床研发，临床试验方案，药物安全警戒和风险评估管理，医学监查和医学信息等经验。主持过全球KALETRA, DEPAKOTE ER, TriCor, Synthroid, HUMIRA, ONGLYZA, BYETTA, BYDURON, 预苗，医疗仪器等上百种产品的安全性临床评估和上市后风险管理。曾参与多家美国公司主导申报新药，疫苗和医疗仪器工作。毕业于同济医科大学和协和医科大学。毕业后，从师于美国北卡罗来纳大学Oliver Smithies教授（2007年诺贝尔奖获得者）的实验室，完成了分子病理学的博士后研究 。

Jan Petracek

PrimeVigilance公司首席执行官

Dr. Jan Petracek qualified as a physician from Charles University in Prague and holds a Master of Science with Distinction in Quality and Safety in Healthcare from Imperial College London. Jan has over 15 years of experience in all areas of pharmacovigilance, being former Head of Risk Management Section at European Medicines Agency, Head of Pharmacovigilance in the Czech Republic, Head of Strategy and Development of the Czech National Authority, and member of CHMP Pharmacovigilance Working Party. He has established guidelines and registries for PASS at national level back in 2003, and since then he was involved in development of standards and regulations surrounding non-interventional studies in safety areas

黄琛

罗氏药品研发中心药品安全科学医学副总监